Drug Summary
Adverse Effects
Class and Mechanism
Indications
Sofosbuvir is indicated for treatment of patients with chronic HCV
- Genotype 1 or 4: sofosbuvir plus peginterferon-alfa plus ribavirin for 12 weeks
- Genotype 2: sofosbuvir plus ribavirin for 12 weeks
- Genotype 3: sofosbuvir plus ribavirin for 24 weeks
For the treatment of patients with HCV-HIV-1 coinfection: the recommendations are the same as listed above.
For patents with genotype 1 HCV who are not eligible to receive interferon: sofosbuvir plus ribavirin for 24 weeks can be considered.
For patients with HCV and hepatocellular carcinoma awaiting liver transplantation: sofosbuvir plus ribavirin for a duration of up to 48 weeks or until liver transplantation, whichever occurs first.
Simeprevir in Combination with Sofosbuvir for HCV Infection: for details see the Simeprevir Drug Summary page and Simeprevir Full Prescribing Information
Daclatasvir in Combination with Sofosbuvir for HCV Infection: for details see the Daclatasvir Drug Summary page and Daclatasvir Full Prescribing Information
Dosing
Cost and Medication Access
Key Drug Interactions
Full Prescribing Information
Figures

